combination therapy with glp-1 receptor agonist and sglt2 inhibitor Agonists Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined | Drugs Mechanisms underlying favorable effects of

All other authors declare no COI

[DOI] [PubMed] [Google Scholar] 42.Van Harken DR, Dixon CW, Heimberg M

The increased risk of kidney stones, on the other hand, might be less familiar

The TAME (Targeting Aging with Metformin) trial is investigating metformin specifically for anti-aging purposes

Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan

Researchers who study the pancreatic peptide hormone system will recognize glucagon as the metabolic counterweight to insulin, and harnessing it pharmacologically opens therapeutic possibilities that the research community has pursued for decades